Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Elicio Therapeutics, Inc. ELTX

Healthcare  —  Biotechnology
1.84 (0.04) (2.13%) as of 25 Sep
Market cap
$53.4M
P/E
0.0×
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Elicio Therapeutics, Inc. (ELTX) Business Profile

Updated before January 2025

Company Overview

Elicio Therapeutics, Inc. (NASDAQ: ELTX) is a biotechnology company dedicated to developing innovative immunotherapies for the treatment of cancer and infectious diseases. Founded in 2011 and headquartered in Cambridge, Massachusetts, Elicio leverages its proprietary Amphiphile (AMP) platform to create therapies that enhance the immune system’s ability to target and eliminate disease. The company was co-founded by Dr. Darrell Irvine, a renowned immunologist and bioengineer, whose groundbreaking research laid the foundation for Elicio’s technology. The leadership team includes CEO Robert Connelly, who brings decades of experience in biotechnology and life sciences, and a board of directors composed of industry veterans and scientific experts.

Core Business Segments

Elicio Therapeutics focuses on two primary business segments:

1. Immuno-Oncology

Elicio’s core focus is on developing immunotherapies that target cancer. The company’s lead product candidate, ELI-002, is an Amphiphile immunotherapy designed to treat KRAS-driven cancers, which are among the most common and challenging to treat. ELI-002 is currently in clinical trials and has shown promise in enhancing immune responses against KRAS mutations, which are prevalent in cancers such as pancreatic, colorectal, and lung cancer.

2. Infectious Diseases

Elicio is also exploring the application of its AMP platform in the development of vaccines for infectious diseases. By enhancing the delivery and presentation of antigens to the immune system, the AMP platform has the potential to create more effective and durable vaccines. While this segment is still in its early stages, it represents a significant growth opportunity for the company.

Business Model

Elicio Therapeutics operates on a research-driven business model that integrates cutting-edge science with strategic partnerships. The company generates revenue primarily through collaborations, licensing agreements, and milestone payments from pharmaceutical partners. By focusing on the development of platform-based therapies, Elicio aims to create a pipeline of products that can address multiple indications, thereby diversifying its revenue streams. The AMP platform serves as the backbone of this strategy, enabling the company to develop a range of immunotherapies and vaccines with broad applications.

Strategic Direction

Elicio Therapeutics is committed to advancing its pipeline of AMP-based therapies while exploring new applications for its technology. Key strategic priorities include:

  • Advancing Clinical Trials: The company is focused on progressing ELI-002 through clinical development, with the goal of achieving regulatory approval and commercialization.
  • Expanding the AMP Platform: Elicio aims to explore additional indications for its AMP technology, including other cancer types and infectious diseases.
  • Sustainability Goals: While not a traditional focus for biotechnology companies, Elicio is committed to sustainable practices in its research and development processes.
  • Strategic Partnerships: The company seeks to establish collaborations with pharmaceutical companies and academic institutions to accelerate the development and commercialization of its therapies.

Competitive Landscape

Elicio Therapeutics operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Moderna, Inc.: Known for its mRNA technology, Moderna is a leader in vaccine development and immunotherapy.
  • BioNTech SE: Another pioneer in mRNA-based therapies, BioNTech focuses on cancer immunotherapy and infectious disease vaccines.
  • Gritstone Bio, Inc.: A direct competitor in the immuno-oncology space, Gritstone develops personalized cancer vaccines and immunotherapies.
  • Adaptimmune Therapeutics: Specializing in T-cell therapies, Adaptimmune is a competitor in the field of cancer immunotherapy.

Elicio differentiates itself through its proprietary AMP platform, which offers unique advantages in antigen delivery and immune activation.

Risk Factors

Like any biotechnology company, Elicio Therapeutics faces several risks, including:

  • Regulatory Risks: The development and approval of new therapies are subject to stringent regulatory requirements, which can delay or prevent commercialization.
  • Market Dependence: The company’s success is heavily reliant on the clinical and commercial success of ELI-002 and other pipeline candidates.
  • Supply Chain Disruptions: Dependence on specialized materials and manufacturing processes makes the company vulnerable to supply chain issues.
  • Competition: The biotechnology sector is highly competitive, with rapid advancements that could render Elicio’s technologies obsolete.
  • Financial Risks: As a pre-revenue company, Elicio depends on external funding to finance its operations, making it vulnerable to market fluctuations and investor sentiment.

Recent Developments

Elicio Therapeutics has made significant progress in recent months, including:

  • Clinical Trials: The company announced positive interim results from its Phase 1/2 clinical trial of ELI-002, demonstrating strong immune responses and a favorable safety profile.
  • Partnerships: Elicio entered into a collaboration with a leading pharmaceutical company to explore the use of its AMP platform in vaccine development.
  • Corporate Strategy: The company recently completed a successful IPO, raising funds to support the advancement of its pipeline and platform technology.
  • Global Developments: The COVID-19 pandemic has highlighted the importance of vaccine innovation, creating new opportunities for Elicio’s AMP platform in infectious disease applications.

Investment Considerations

Strengths:

  • Innovative Technology: The AMP platform offers a unique approach to immunotherapy and vaccine development.
  • Strong Pipeline: ELI-002 has shown promising results in early clinical trials, targeting a significant unmet medical need.
  • Experienced Leadership: The management team has a proven track record in biotechnology and drug development.
  • Strategic Partnerships: Collaborations with pharmaceutical companies provide additional resources and expertise.

Risks:

  • Early-Stage Company: As a pre-revenue company, Elicio faces financial risks and depends on external funding.
  • Regulatory Hurdles: The approval process for new therapies is lengthy and uncertain.
  • Market Competition: The biotechnology sector is highly competitive, with rapid advancements that could impact Elicio’s market position.

Conclusion

Elicio Therapeutics is a promising biotechnology company with a strong focus on immunotherapy and vaccine development. Its proprietary AMP platform positions it as a leader in antigen delivery and immune activation, offering significant potential for addressing unmet medical needs in cancer and infectious diseases. While the company faces typical risks associated with early-stage biotech firms, its innovative technology, strong pipeline, and experienced leadership provide a solid foundation for future growth. As Elicio advances its clinical programs and explores new applications for its platform, it is well-positioned to make a meaningful impact in the biotechnology sector.